Henning Schwanhäusser is a serial entrepreneur and investor in a number of high-tech start-up companies in IT and Biotech. Henning was co-founder & Board member of Switzerland-based NBE-Therapeutics and instrumental in developing the company's strategy, leading to the successful trade sale of NBE-Therapeutics to Boehringer Ingelheim, Germany, for $ 1.4bn in 2021.

He is currently an advisor for Dahlia Robotics in Munich, Germany, and an investor in Viou in London, GB. Henning was founder and CEO of IT company AccapiStudio SRL, in Vicenza, Italy, from 2002 to 2015, a member of the supervisory board of Sketchin from 2013 to 2016, a company in Ticino, Switzerland, and a seed investor in SparkFabrik in Milano, Italy, from 2012 to 2019. Since 2021, Henning has also been a member of the Board of Advisors of Schwanhäußer Industrie Holding GmbH & Co. KG in Heroldsberg, Germany.

Henning holds a diploma in Business Engineering from the University of Padova, Italy, and a diploma in Technology Entrepreneurship from the Executive School of Management of the University St. Gallen, Switzerland.